Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis

Digestive Diseases and Sciences

Volumn 61, Issue 10, 2016, Pages 2776-2783

  Chak, Eric W ^a   Sarkar, Souvik ^a   Bowlus, Christopher ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic hepatitis B; Chronic hepatitis C; Disparities; Linkage to care; Screening

Indexed keywords

CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFECTION RISK; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; ASIAN AMERICAN; COMMUNICATION BARRIER; CULTURAL ANTHROPOLOGY; DRUG USE; EARLY DIAGNOSIS; EARLY INTERVENTION; ELECTRONIC HEALTH RECORD; EPIDEMIOLOGY; ETHNOLOGY; HEALTH CARE DELIVERY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TUMOR; MASS SCREENING; MORTALITY; OCEANIC ANCESTRY GROUP; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TOTAL QUALITY MANAGEMENT; UNITED STATES;

ASIAN AMERICANS; CARCINOMA, HEPATOCELLULAR; COMMUNICATION BARRIERS; CULTURE; DELIVERY OF HEALTH CARE; DRUG USERS; EARLY DIAGNOSIS; EARLY MEDICAL INTERVENTION; ELECTRONIC HEALTH RECORDS; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MASS SCREENING; OCEANIC ANCESTRY GROUP; PREVALENCE; QUALITY IMPROVEMENT; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 84987623264     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4205-3     Document Type: Review

References (75)

1. Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the united states in the era of vaccination. J Infect Dis. 2010;202:192–201.
2. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the united states by country of origin. Hepatology. 2012;56:422–433.
3. Center for Disease Control (CDC). Number and rate of hepatitis B-related deaths, by demographic characteristics and year—United States, 2009–2013. Updated June 25, 2015; April 25, 2016.
4. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–1555.
5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128.
6. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7:2127–2132.
7. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
8. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
9. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283.
10. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067–1077.
11. Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284–306.
12. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–288, 288.e1.
13. Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the virahep-C study. J Hepatol. 2012;57:946–952.
14. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509–516.e1.
15. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–2593.
16. Rutter K, Stattermayer AF, Beinhardt S, et al. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015;41:521–531.
17. Moorman AC, Xing J, Ko S, et al. Late diagnosis of hepatitis C virus infection in the chronic hepatitis cohort study (CHeCS): missed opportunities for intervention. Hepatology. 2015;61:1479–1484.
18. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–1861.
19. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the US preventive services task force. Ann Intern Med. 2013;158:101–108.
20. Cook N, Turse EP, Garcia AS, Hardigan P, Amofah SA. Hepatitis C virus infection screening within community health centers. J Am Osteopath Assoc. 2016;116:6–11.
21. Centers for Disease Control and Prevention (CDC). Vital signs: evaluation of hepatitis C virus infection testing and reporting—eight U.S. sites, 2005–2011. MMWR Morb Mortal Wkly Rep. 2013;62:357–361.
22. Centers for Disease Control and Prevention (CDC). Locations and reasons for initial testing for hepatitis C infection—chronic hepatitis cohort study, united states, 2006–2010. MMWR Morb Mortal Wkly Rep. 2013;62:645–648.
23. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.
24. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the united states: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60:691–698.
25. Backus LI, Belperio PS, Loomis TP, Yip GH, Mole LA. Hepatitis C virus screening and prevalence among US veterans in department of veterans affairs care. JAMA Intern Med. 2013;173:1549–1552.
26. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61:1–32.
27. Moyer VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159:349–357.
28. Scofield J, Mayer R. The affordable care act and the silent epidemic: increasing viral hepatitis response through health reform. The National Alliance of State & Territorial AIDS Directors (NASTAD). 2013.
29. Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology. 2016;63:388–397.
30. Institute of Medicine (US) Committee on the Prevention and Control of Viral Hepatitis Infection. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C http://Www.nap.edu/catalog/12793.html. 2010.
31. Beckett GA, Ramirez G, Vanderhoff A, et al. Early identification and linkage to care of persons with chronic hepatitis B virus infection—three U.S. sites, 2012–2014. MMWR Morb Mortal Wkly Rep. 2014;63:399–401.
32. Hu KQ. Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol. 2008;103:1824–1833.
33. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109:542–553.
34. LeFevre ML, U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2014;161:58–66.
35. Center for Disease Control (CDC). Prevention of HIV/AIDS, viral hepatitis, and TB through health care. Updated November 7, 2014; April 25, 2016.
36. U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in pregnancy: U.S. preventive services task force reaffirmation recommendation statement. Ann Intern Med. 2009;150:869–873, W154.
37. Chen H, Tu SP, Teh CZ, et al. Lay beliefs about hepatitis among North American Chinese: implications for hepatitis prevention. J Community Health. 2006;31:94–112.
38. Wu CA, Lin SY, So SK, Chang ET. Hepatitis B and liver cancer knowledge and preventive practices among Asian Americans in the San Francisco bay area, California. Asian Pac J Cancer Prev. 2007;8:127–134.
39. Chao SD, Wang BM, Chang ET, Ma L, So SK. Medical training fails to prepare providers to care for patients with chronic hepatitis B infection. World J Gastroenterol. 2015;21:6914–6923.
40. Robotin M, Patton Y, George J. Getting it right: the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. Int J Gen Med. 2013;6:115–122.
41. Upadhyaya N, Chang R, Davis C, Conti MC, Salinas-Garcia D, Tang H. Chronic hepatitis B: perceptions in asian american communities and diagnosis and management practices among primary care physicians. Postgrad Med. 2010;122:165–175.
42. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55:1047–1055.
43. Sarkar M, Shvachko VA, Ready JB, et al. Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci. 2014;59:2100–2108.
44. Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013;56:40–50.
45. Chen MS Jr, Fang DM, Stewart SL, et al. Increasing hepatitis B screening for among adults: results from a randomized controlled community-based study. Cancer Epidemiol Biomark Prev. 2013;22:782–791.
46. Taylor VM, Bastani R, Burke N, et al. Evaluation of a hepatitis B lay health worker intervention for cambodian Americans. J Community Health. 2013;38:546–553.
47. Bastani R, Glenn BA, Maxwell AE, et al. Cluster-randomized trial to increase hepatitis B testing among Koreans in Los Angeles. Cancer Epidemiol Biomarkers Prev. 2015;24:1341–1349.
48. Strom BL, Schinnar R, Aberra F, et al. Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction: a randomized controlled trial. Arch Intern Med. 2010;170:1578–1583.
49. Strom BL, Schinnar R, Bilker W, Hennessy S, Leonard CE, Pifer E. Randomized clinical trial of a customized electronic alert requiring an affirmative response compared to a control group receiving a commercial passive CPOE alert: NSAID—warfarin co-prescribing as a test case. J Am Med Inform Assoc. 2010;17:411–415.
50. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352:969–977.
51. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001;345:965–970.
52. Wilson FP, Shashaty M, Testani J, et al. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet. 2015;385:1966–1974.
53. Hsu L, Bowlus CL, Stewart SL, et al. Electronic messages increase hepatitis B screening in at-risk Asian American patients: a randomized, controlled trial. Dig Dis Sci. 2013;58:807–814.
54. Lauderdale D, Kestenbaum B. Asian american ethnic identification by surname. Popul Res Policy Rev. 2000;19:283–300.
55. US Department of Health and Human Services. Combating the silent epidemic: Action plan for the prevention and treatment of viral hepatitis. http://Www.hhs.gov/ash/initiatives/hepatitis/.
56. McMahon BJ, Block J, Haber B, et al. Internist diagnosis and management of chronic hepatitis B virus infection. Am J Med. 2012;125:1063–1067.
57. Perumalswami PV, Factor SH, Kapelusznik L, et al. Hepatitis outreach network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58:890–897.
58. Backus LI, Belperio PS, Loomis TP, Mole LA. Impact of race/ethnicity and gender on HCV screening and prevalence among U.S. veterans in department of veterans affairs care. Am J Public Health. 2014;104:S555–S561.
59. Linas BP, Hu H, Barter DM, Horberg M. Hepatitis C screening trends in a large integrated health system. Am J Med. 2014;127:398–405.
60. Sarkar S, Esserman D, Levin F, Justice A, Lim J. Variability of hepatitis C screening in birth age cohort U.S. veterans born 1945–1965: national analysis of 4.2 million veterans 2000–2013. Program and abstracts of Digestive Disease Week; May 16–19, 2015. 2015.
61. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41:88–96.
62. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–1101.
63. Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015;7:2323–2330.
64. He T, Li K, Roberts MS, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164:84–92.
65. Batash S, Khaykis I, Raicht RF, Bini EJ. High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. Am J Gastroenterol. 2008;103:922–927.
66. Perumalswami PV, Miller FDW, Orabee H, et al. Hepatitis C screening beyond CDC guidelines in an egyptian immigrant community. Liver Int. 2014;34:253–258.
67. Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology. 2015;61:783–789.
68. Alavi M, Raffa JD, Deans GD, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int. 2014;34:1198–1206.
69. Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment—extension for community healthcare outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52:1124–1133.
70. Backus LI, Belperio PS, Loomis TP, Yip GH, Mole LA. Hepatitis C virus screening and prevalence among US veterans in department of veterans affairs care. JAMA Intern Med. 2013;173:1549–1552.
71. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199–2207.
72. Turner BJ, Taylor BS, Hanson J, et al. High priority for hepatitis C screening in safety net hospitals: results from a prospective cohort of 4582 hospitalized baby boomers. Hepatology. 2015;62:1388–1395.
73. Galbraith JW, Franco RA, Donnelly JP, et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology. 2015;61:776–782.
74. Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol. 2013;108:981–989.
75. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the united states. Dig Liver Dis. 2011;43:66–72.